Reference : Management of severe preeclampsia
Scientific journals : Article
Human health sciences : Anesthesia & intensive care
Human health sciences : Reproductive medicine (gynecology, andrology, obstetrics)
Management of severe preeclampsia
Brichant, Géraldine [Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
Dewandre, Pierre-Yves mailto [Université de Liège - ULiège > > Anesthésie et réanimation >]
Foidart, Jean-Michel mailto [Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement >]
Brichant, Jean-François mailto [Université de Liège - ULiège > Département des sciences cliniques > Anesthésie et réanimation >]
Acta Clinica Belgica
Acta Clinica Belgica
Yes (verified by ORBi)
[en] Severe preeclampsia ; Eclampsia ; HELLP
[en] Features of severe preeclampsia include severe proteinuric hypertension and symptoms of central nervous system dysfunction, hepatocellular injury, thrombocytopenia, oliguria, pulmonary oedema, cerebrovascular accident and severe intrauterine growth restriction. Women with severe preeclampsia must be hospitalized to confirm the diagnosis, to assess the severity of the disease, to monitor the progression of the disease and to try to stabilize the disease. Severe preeclampsia may be managed expectantly, in selected cases. The objective of expectant management in these patients is to improve neonatal outcome. Expectant management is based on antihypertensive treatment and prevention of end organ dysfunction. Antihypertensive treatment improves maternal outcome but has the potential to be deleterious for the foetus. Plasma volume expansion has been suggested for severe preeclampsia but trials failed to show any benefit. Magnesium sulfate is the anticonvulsivant of choice to treat or prevent eclampsia when indicated. Antenatal corticosteroids are recommended in severely preeclamptic women with 26-34 weeks gestation. Timing of delivery is based upon gestational age, severity of preeclampsia, maternal and foetal risks.

File(s) associated to this reference

Fulltext file(s):

Restricted access
539.pdfPublisher postprint797.38 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.